Summary Eg5 (kinesin spindle protein) is a microtubule motor protein, essential for centrosome separation during mitosis. This Phase I/II, open-label, multicenter, two-part study investigated AZD4877, a potent Eg5 inhibitor, in patients with acute myeloid leukemia. Primary objectives were to determine the maximum tolerated dose (MTD) (part A), assess efficacy (part B) and determine the pharmacokinetic profile (parts A and B). Secondary objectives included assessment of safety and tolerability. AZD4877 was administered at a range of doses (2, 4, 7, 10, 13, 16 and 18 mg/day) as a 1-hour intravenous infusion on three consecutive days of a continuous 2-week schedule. The MTD in part A was defined as 16 mg/day based on dose-limiting stomatitis at 16 and 18 mg/day, hyperbilirubinemia at 16 mg/day and palmarplantar erythrodysesthesia syndrome at 18 mg/day. Systemic exposure to AZD4877 generally increased with increasing dose whereas half-life was not dose dependent. No evaluable patients experienced a complete remission (CR) or CR with incomplete blood count recovery (CRi), demonstrating no evidence of AZD4877 efficacy in this population. Evidence of monoasters in all but the 4 mg/day dose group provided proof of mechanism for AZD4877. This study was terminated due to lack of efficacy. (ClinicalTrials.gov identifier NCT00486265).
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Keywords AML . Eg5 inhibitor . Phase I/II . Safety . MTD . Pharmacokinetics Introduction Acute myeloid leukemia (AML) accounts for 12,330 of the 43,050 new cases of leukemia diagnosed ever year in the United States [1] . The primary goal of treatment in patients with AML is to achieve complete remission. This is normally accomplished by initial induction treatment with cytotoxic chemotherapy agents. Although complete remission can be achieved in the majority of young adult patients, ultimate cure depends on disease eradication through the administration of post-remission chemotherapy. Forty to fifty percent of older patients can achieve a complete remission, however less than 10% are long-term survivors, and the cure rate of older patients (which represent the majority of patients with AML) has only minimally improved over the past three decades [2, 3] . Thus, there is a need to develop treatments for AML that are more effective, especially for the elderly who are unable to tolerate intensive chemotherapy regimens.
A rationale has been proposed for targeting the mitotic kinesin Eg5 for treatment of patients with AML; Eg5, an ATPdependent microtubule motor protein is required for the correct formation of the mitotic spindle; expression of Eg5 is elevated in a number of human proliferative tissues, most notably the bone marrow, as well as in a number of solid tumors and leukemias [4] [5] [6] . Indeed, inhibition of Eg5 has been shown to induce the formation of monopolar mitotic spindles ('monoasters') in replicating cells as a result of activation of the spindle assembly checkpoint and induction of cell cycle arrest during the mitotic phase, which leads to cell death by apoptosis [7] [8] [9] . Furthermore, Eg5 inhibition has been shown to promote cell death in a number of cancer cell lines and tumor xenograft models [10] [11] [12] [13] [14] . In addition, the Eg5 inhibitor ARRY-520 has been shown to cause apoptosis in AML progenitor cells in vitro [15] .
Unlike first generation antimitotic agents such as the taxanes and vinca alkaloids, Eg5 inhibitors only target cells that are in mitosis. Therefore they are not expected to have an effect on non-proliferating adult tissue such as the peripheral nervous system [16, 17] . The kinesin spindle protein (KSP) Eg5 has emerged as a novel target that has a selective action on the mitotic pathway that acts only on dividing cells. Consequently, treatment with Eg5 agents is not anticipated to cause the neurotoxic side effects commonly observed with traditional antimitotic agents [4, 14] .
AZD4877 is a potent inhibitor of Eg5 that has been shown to disrupt mitotic spindle assembly, leading to mitotic arrest and cell death [18] . Consistent with this mode of action, AZD4877 was shown to induce the formation of monoasters and cell death in tumor xenograft models and in a broad range of both solid and hematologic tumor cell lines [18] . Previously reported investigations of monoasters in peripheral blood mononuclear cells (PBMCs) of patients from the present study have shown that monoasters were detected at all dose levels evaluated (2, 7, 10, 13, and 18 mg/day), consistent with pharmacodynamic activity of AZD4877 in patients with AML [19] .
The aim of this Phase I/II study was to determine the maximum tolerated dose (MTD) of AZD4877 and to evaluate the efficacy and pharmacokinetic (PK) profile of AZD4877 in patients with recurrent or refractory AML.
Methods

Patients
Patients aged ≥18 years were eligible for inclusion in the study if they had relapsed or refractory AML for which standard therapies were not anticipated to result in durable remission (part A), or if they had AML with a maximum of two prior relapses or failure to achieve remission after at least one attempt at induction treatment (part B All patients provided written, informed consent. The study was approved by the independent ethics committee for each trial center and was conducted in accordance with the Declaration of Helsinki [20] , consistent with Good Clinical Practice and the AstraZeneca policy on bioethics.
Study design
This was a Phase I/II, open-label, multicenter, two-part study carried out across five sites in North America and Canada (AstraZeneca study identifier: D2782C00007; ClinicalTrials.gov identifier: NCT00486265).
Part A was a Phase I, open-label, dose-escalation study to determine the MTD of AZD4877 (initial dose 2 mg/day) when administered as an induction course of a 1-hour intravenous (iv) infusion, on three consecutive days, at the beginning of a 2-week schedule for a total of two induction courses. Patients could continue on treatment and receive up to four 2-day consolidation courses at continuous 2-week intervals, provided that there was evidence of complete remission. Initial recruitment to each AZD4877 dose cohort was a minimum of three patients, with a maximum of six evaluable patients in each dose level cohort prior to dose escalation/reduction. Dose escalation only occurred when no patients in a cohort of three evaluable patients or one of six evaluable patients experienced a dose-limiting toxicity (DLT). An evaluable patient in part A was defined as a patient who had completed one 3-day induction course of AZD4877 and had been followed until day 15, or had discontinued from study treatment due to disease progression and was observed until day 10, or a patient who experienced a DLT within the initial 15 days of treatment. A minimum of six evaluable patients were to have been treated at the MTD before part B commenced.
Part B was a phase II, open-label study that assessed the efficacy of AZD4877 administered at the MTD defined in part A. In Part B, a Simon optimal two-stage design [21] was planned based on the rate of complete remission (CR) or CR with incomplete blood count recovery (CRi). Nineteen evaluable patients were to be initially enrolled and followed up for a minimum of 28 days and a maximum of 4 months (for patients with a CR or CRi). If three or fewer of these patients achieved a CR or CRi, the study was to be stopped due to lack of efficacy. If four or more patients achieved a CR or CRi, an additional 14 patients were to be enrolled and treated. In part B, for the purpose of determining efficacy, an evaluable patient was defined as a patient who had received a minimum of one 3-day induction course of AZD4877. For evaluation of safety and tolerability patients must have received at least one dose of AZD4877.
In both parts A and B, patients who achieved CR or CRi after one or two induction courses could remain on the study to receive a maximum of four 2-day consolidation courses administered 7-21 days after recovery of blood cell counts to CTCAE grade ≤1.
The initial recruitment into part B of this open-label study was rapid. Unvalidated reports from the study sites indicated that none of the recruited patients had experienced a CR or CRi. Therefore recruitment into part B of the study was suspended in May 2009. Part B was designed to test the alternative hypothesis that the rate of CR or CRi was 0.35 or above, as a sign of efficacy, versus the null hypothesis that this rate was 0.15 or below. No CR or CRi responses were seen in the first eight patients enrolled. If the alternative hypothesis were true (ie P½CR þ CRi ¼ 0:35 or above), then the chance of seeing zero CR or CRi responses would have been (1-0.35) 8 =0.032 (3.2%), or less. Also, with 0 out of eight patients responding, only 3.2% of the Bayesian posterior distribution of the P(CR + CRi) is above 0.35 (using non-informative prior). Therefore, based on the data from eight patients, it was considered unlikely that P(CR + CRi) is 0.35 or above, and the study was discontinued. Nine evaluable patients were enrolled at study termination.
Objectives
The primary objectives of this study were to identify the MTD of AZD4877 based on assessment of DLT (part A), assess the efficacy of AZD4877 based on the rate of CR and CRi (part B), and determine the PK profile of AZD4877 (parts A and B). The secondary objectives were to evaluate the safety and tolerability of AZD4877 (parts A and B) and to further assess the effect of AZD4877 on the rate and duration of CR, CRi, partial remission (PR) and overall response (part B). Exploratory objectives included the evaluation of the mechanism of action of AZD4877 by assessment of monoaster formation in PBMCs.
Assessments
The MTD of AZD4877 was defined as the highest dose at which no more than one of six evaluable patients experienced a DLT during the first induction course. DLTs were defined as CTCAE grade 3 or 4 hemolysis; CTCAE grade 3 or 4 non-hematological toxicity; AST or ALT CTCAE grade 3 (for >7 days), or grade 4 (of any duration) except for patients with grade 3 transaminases due to leukemic organ involvement at baseline; CTCAE grade 2 diarrhea for >4 days despite aggressive outpatient management; CTCAE grade 3 or 4 vomiting for >24 h despite suitable anti-emetics, or any other toxicity related to study treatment considered to be a DLT by the investigator.
Safety and tolerability were evaluated by assessment of AEs according to CTCAE version 3.0. Samples for laboratory assessments (clinical chemistry and hematology) were taken pre-dose on days 1, 2, 3 (hematology only) and on day 8 of induction courses 1 and 2, and urinalysis parameters were measured pre-dose on day 1 and at the end of the infusion on day 3 of induction courses 1 and 2.
Blood samples were collected for the determination of plasma concentrations of AZD4877 pre-dose on days 1, 2 and 3, and on days 4, 5 and 8 of induction course 1. PK parameters were evaluated following day 3 of the first induction course and included maximum plasma drug concentration (C max ), plasma drug concentration 24 h after administration (C 24h ), area under the concentration-time curve from zero to infinity (AUC 0-∞ ), area under the concentration-time curve from zero to 24 h (AUC 0-24h ) and half-life (t ½λz ) associated with the terminal elimination rate constant (λ z ) of a semi-logarithmic concentration-time curve. Non-compartmental methods were used for the evaluation of the plasma concentration-time data and C max was determined by inspection of the concentration-time profiles. Where possible, λ z was calculated by log-linear regression of the terminal portion of the concentration-time profiles, and t ½λz was defined as 0.6932/λ Z . AUC 0-24h was determined using the linear trapezoidal rule and, where appropriate, AUC 0-24h was extrapolated to infinity using λ z to obtain AUC 0-∞ . The methods for the PK parameter assessments and calculations reported in this study have been described previously [22] .
Efficacy of AZD4877 was determined by investigator assessment of bone marrow response using modified Cheson response criteria for AML [23, 24] . Bone marrow response was categorized as CR, CRi, or PR and the duration of response was defined as time from first documentation of CR, or CRi to relapse.
The presence of monoasters in PBMCs was assessed predose, 6-8 and 24 h after the first infusion of AZD4877. PBMCs prepared from whole blood samples using cell preparation tubes (Vacutainer CPTs; Becton Dickinson, Franklin Lakes, NJ, USA) were washed in phosphate buffered saline, centrifuged onto glass slides and air dried. Immunohistochemical staining for α-tubulin was performed on the Ventana Discovery XT system slide stainer using the OmniMap detection kit (Ventana, Tucson, AZ, USA) according to the manufacturer's instructions. Total cell counts were determined by image analysis using Aperio IHC Nuclear Algorithm software (Aperio Technologies Inc. Vista, CA, USA), and monoasters were scored manually. Monoaster counts were expressed as number per 10,000 PBMCs with a mean of 100,000 cells counted for each assessment.
Statistical analysis
Due to early termination of part B, and lack of CR and CRi responses, no formal statistical analyses of efficacy were conducted. Statistical analyses were restricted to summaries of all data from all treated patients to assess safety, tolerability, PK, pharmacodynamics and initial indications of anti-leukemic activity of AZD4877.
Results
Patient characteristics
A total of 47 patients were enrolled in the study, 39 of whom received at least one dose of AZD4877 and were evaluable for safety (30 patients in part A and nine patients in part B) ( Table 1 ). Two patients in part A were excluded from DLT and PK assessments because they did not receive the complete 3-day induction course of AZD4877, one because of voluntary discontinuation from AZD4877 treatment (2 mg/day dose cohort) and the other because of discontinuation due to CTCAE grade 3 hyperbilirubinemia (16 mg/day dose cohort). All patients recruited into part B were evaluable for safety, efficacy and PK assessment.
The mean age of patients was 62.4 years (range 23-84 years), 32 patients (82%) were Caucasian, and 26 patients (67%) were male. All patients received prior treatment regimens; 18 patients (46%) had initial induction failure, and 21 patients (54%) did not. Thirty-two patients (82%) discontinued the study due to a lack of therapeutic response, three (7.7%) patients voluntarily discontinued, two patients (5.1%) discontinued due to an AE (hyperbilirubinemia; Stevens-Johnson syndrome), one patient (2.6%) died due to disease progression and one patient (2.6%) discontinued for other reasons.
Twenty-two patients (56%) received a single, complete, 3-day induction course (including five patients in part B) and 15 patients (39%) completed two induction courses (including five patients in part B). Two patients proceeded to receive two consolidation courses each, one patient each in the 7 mg/day and 10 mg/day dose cohorts. The median (range) number of doses of AZD4877 received was three (1-10) and the median (range) total dose received was 48 mg (2-108 mg).
Safety profile
During the first induction course, three patients experienced a total of four DLTs, one patient receiving AZD4877 16 mg/day and two patients receiving AZD4877 18 mg/day ( Table 2 ). The MTD for AZD4877 was defined as 16 mg/day.
All patients experienced at least one AE, the most commonly reported were diarrhea (n=18), hypokalemia (n=16), nausea (n=14), fatigue (n=12) and hypocalcemia (n=12). Twenty-four patients experienced CTCAE grade ≥3, of which hypokalemia (n=8) was the most commonly reported (Table 3) . Serious adverse events (SAEs) occurred in 13 patients across all dose groups. Mucosal inflammation was the only SAE reported in more than one patient, occurring in three patients in part B. Seven patients had a total of nine SAEs that were considered to be causally related to AZD4877 treatment (by patient, these events were: atrial flutter; diverticulitis and hyperbilirubinemia; mucosal inflammation [two separate patients]; mucosal inflammation and Stevens-Johnson syndrome; palmar-plantar erythrodysesthesia syndrome; and stomatitis). Six patients died due to disease progression (only one of whom discontinued the study due to death), two of whom had fatal SAEs reported as Gender, n (%) Male 4 (67) 1 (33) 3 (75) 3 (100) 1 (33) 6 (86) 3 (75) 5 (56) 26 ( ) 1 (14) 1 (25) 4 (44) 13 (33) Race, n (%) Caucasian 4 (67) 1 (33) 3 (75) 2 (67) 3 (100) 7 (100) 4 (100) 8 (89) 32 ( (11) 6 (15) Restricted activity 3 (50) 1 (33) 2 (50) 2 (67) 2 (67) 5 (71) 3 (75) 7 (78) 25 (64) In bed ≤50% of the time 2 (29) 1 (25) 3 (33) 8 ( 3 (100) 1 (25) 3 (100) 1 (33) 2 (29) 2 (50) 4 (44) 21 (54) ECOG, Eastern Cooperative Oncology Group; SD, standard deviation secondary causes of death (cerebral hemorrhage and fungal pneumonia in the 2 and 10 mg/day dose cohorts, respectively). One patient discontinued the study due to CTCAE grade 3 hyperbilirubinemia, which was considered by the investigator to be causally related to AZD4877 treatment. CTCAE grade ≥3 clinical chemistry values were reported in 23 patients. The events included high magnesium, high potassium and low serum albumin. These abnormalities showed no apparent dose relationship with AZD4877 and were consistent with those typically found in patients with AML. No clinically significant changes in vital signs or ECG were reported.
Pharmacokinetics, pharmacodynamics and efficacy
Thirty-seven patients had evaluable PK data (Table 4) . Exposure to AZD4877 (C max , C 24h , AUC 0-∞ and AUC 0-24 ) increased in an approximately dose-proportional manner, whereas the t ½λz of AZD4877 did not appear to be dose dependent.
No remissions or responses according to the Cheson criteria were reported during parts A or B of the study. In part B, all nine patients had treatment failure, which was attributed to resistant disease. The study was terminated due to a lack of efficacy following the evaluation of the nine patients in part B. PBMCs from 12 patients in part A were evaluated for the exploratory endpoint of monoaster detection. Monoasters were detected in nine patients 6 h after the start of AZD4877 treatment on day 1 (n=1 patient, 2 mg/day, 7 mg/day, 10 mg/day and 13 mg/day; n=2 patients, 18 mg/day; n=3 patients, 16 mg/day) and in four patients (n=2 patients, 16 mg/day; n=2 patients, 18 mg/day) 24 h following AZD4877 treatment on day 2 (Fig. 1) .
Discussion
The MTD of AZD4877, when administered as a 1-hour iv infusion on three consecutive days, was defined as 16 mg/day. In a study of patients with solid tumors, DLTs of neutropenia were observed at doses of greater than 30 mg, administered as three weekly 1-hour iv infusions in a 28-day schedule [25] . However, in the current study neutropenia was not reported as a DLT and the DLTs were stomatitis (16 and 18 mg/day cohorts), hyperbilirubinemia (16 mg/day cohort) and palmar-plantar erythrodysesthesia syndrome (18 mg/day cohort). The AEs of stomatitis and mucosal inflammation occurred in a dose-dependent manner and are consistent with the mechanism of action of AZD4877 as this agent directly targets proliferating tissues. All patients had at least one AE, with diarrhea, hypokalemia, nausea, fatigue and hypocalcemia the most commonly reported. Hypokalemia, hypophosphatemia and stomatitis accounted for the highest number of CTCAE grade ≥3 events. Mucosal inflammation was the only SAE reported in more than one patient. Other commonly reported AEs (hypokalemia and hypocalcemia) were consistent with those in patients with AML [26] .
PK parameters in the present study were consistent with data from another clinical trial of AZD4877 [25] . Although there was some variability across the dose range, systemic exposure to AZD4877 was approximately dose proportional, supporting an approximately linear PK profile. The half-life of AZD4877 was approximately 17 h. The variability in PK parameters observed in the current study may be due to the small number of patients in each dose group. Proof of mechanism was confirmed by the detection of monoasters in PBMCs at all dosage levels studied. There were no evaluable patients at the AZD4877 4 mg dose, so this cohort was not studied. On day 1, monoasters were detected in PBMCs from patients at all doses in a dosedependent manner, whereas monoasters were only detected in the 16 and 18 mg/day dose cohorts on day 2, signifying a greater duration of response at these doses. Despite evidence of monoasters, there were no complete or partial remissions to AZD4877 treatment. Limited clinical efficacy has also been reported in another clinical trial of AZD4877 [25] , and in trials of other Eg5 agents in patients with solid tumors and malignant melanoma [27] [28] [29] [30] [31] . This may be due to insufficiently high and/or sustained exposure to Eg5 agents because of DLTs. Notably, in a Phase I trial of AZD4877 in patients with advanced solid malignancies, the longest duration of stable disease was associated with the highest dose studied [25] . Although AZD4877 and Eg5 inhibitors in general have proven highly effective at killing tumor cells in preclinical models, their efficacy in humans appears to be limited by an insufficient therapeutic window. Ongoing clinical trials of other Eg5 inhibitors such as Array 520 and 4SC-205 will confirm if this is true for all drugs of this type.
In conclusion, AZD4877 was generally well tolerated, and demonstrated an acceptable PK profile in patients with AML. Several KSP inhibitors such as MK0371, Array 520 and SB-715992/ispinesib are currently in clinical trials for various solid tumors. Ispinesib has demonstrated clinical activity in a Phase II study of patients with platinum/taxane refractory or resistant relapsed ovarian cancer [32] . In the current Phase I study of patients with AML, there was evidence of monoaster formation, which was indicative of the proof of mechanism for Eg5 inhibition, however, the lack of clinical efficacy in part B resulted in the early termination of the study. Based on the relative lack of clinical efficacy in this and other completed Phase I and II trials of AZD4877, further development of this agent as an anticancer therapy is not planned. Future challenges of developing KSP inhibitors in leukemia have to carefully consider the kinetics of the disease and include combined synergistic strategies with existing chemotherapeutic agents.
